DETROIT--(BUSINESS WIRE)--Asterand plc (LSE: ATD), a leading provider of human tissue and human tissue-based services to pharmaceutical and biotechnology companies engaged in drug discovery, today announced that it has launched Good Laboratory Practice (GLP) compliant molecular pathology services supporting preclinical safety studies. The Company’s first new service offering will be tissue cross reactivity testing for therapeutic antibodies in order to supply clients with critical data required by regulatory authorities such as the Food & Drug Administration (FDA) and the European Medicines Agency (EMEA),for investigational new drug submissions. Acceptance as a member of the UK GLP Compliance Monitoring Programme will also allow Asterand to expand its offering of GLP compliant preclinical services to its pharmaceutical and biotech clients.
